γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments by Rebecca Rawlinson & Andrew J Massey
Rawlinson and Massey BMC Cancer 2014, 14:483
http://www.biomedcentral.com/1471-2407/14/483RESEARCH ARTICLE Open AccessγH2AX and Chk1 phosphorylation as predictive
pharmacodynamic biomarkers of Chk1
inhibitor-chemotherapy combination treatments
Rebecca Rawlinson and Andrew J Massey*Abstract
Background: Chk1 inhibitors are currently in clinical trials in combination with a range of cytotoxic agents and
have the potential to potentiate the clinical activity of a large number of standard of care chemotherapeutic
agents. Utilizing pharmacodynamic biomarkers to optimize drug dose and scheduling in these trials could greatly
enhance the likelihood of clinical success.
Methods: In this study, we evaluated the in vitro potentiation of the cytotoxicity of a range of cytotoxic
chemotherapeutic drugs by the novel Chk1 inhibitor V158411 in p53 mutant colon cancer cells. Pharmacodynamic
biomarkers were evaluated in vitro.
Results: V158411 potentiated the cytotoxicity of a range of chemotherapeutic agents with distinct mechanisms of
action in p53 mutant colon cancer cell lines grown in anchorage dependent or independent culture conditions. Analysis
of pharmacodynamic biomarker changes identified dependencies on the chemotherapeutic agent, the concentration of
the chemotherapeutic and the duration of time between combination treatment and biomarker analysis. A reduction in
total Chk1 and S296/S317/S345 phosphorylation occurred consistently with all cytotoxics in combination with V158411
but did not predict cell line potentiation. Induction of γH2AX levels was chemotherapeutic dependent and correlated
closely with potentiation of gemcitabine and camptothecin in p53 mutant colon cancer cells.
Conclusions: Our results suggest that Chk1 phosphorylation could be a useful biomarker for monitoring inhibition of
Chk1 activity in clinical trials involving a range of V158411-chemotherapy combinations and γH2AX induction as a
predictor of potentiation in combinations containing gemcitabine or camptothecin.
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The DNA damage response (DDR) is a complex network
of signaling pathways that have evolved to protect cells
from DNA damage or interference with DNA synthesis.
A series of cell cycle checkpoints at G1/S, intra-S or S,
and G2/M protect cells from undergoing aberrant
division in the presence of DNA damage thereby allowing
DNA repair, regulation of transcription and apoptosis
[1-4]. The serine-threonine checkpoint kinases Chk1 and
Chk2 are often described as the “central transducers” of
the DDR and are activated by the ATM kinase in response
to DNA breaks and ATR kinase by single-stranded regions
of DNA and form the key link between the sensing kinases* Correspondence: a.massey@vernalis.com
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article, unless otherwise stated.ATM/ATR and the cell cycle machinery. Recognition of
DNA double strand breaks by the Mre11 complex
(Mre11, Rad50 and Nbs1) or replication stress by the
Rad9-Hus1-Rad1 complex results in the activation of
the ATR and ATM kinases respectively. These kinases,
in turn, activate the effector kinases Chk1 and Chk2.
Chk1 activation occurs predominantly by three phos-
phorylation events on S317 and 345 by ATR [5,6] and
auto-phosphorylation on S296 [7]. Chk1 and Chk2
negatively regulate the Cdc25 family of phosphatases
thereby preventing cell cycle progression as well as
directly modulating repair proteins resulting in effective
lesion repair. Biochemical and genetic studies have
demonstrated Chk1 to be essential and indispensable
for the S- and G2/M checkpoints [1,8]. In the vastd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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of the G1/S checkpoint) is mutated or functionally inac-
tivated, rendering cancer cells reliant on Chk1/Chk2 for
checkpoint activation, in the presence of endogenous or
exogenous DNA damage.
DNA damaging cytotoxic chemotherapeutic agents
and ionizing radiation are the mainstay of current cancer
treatment regimens. These agents target the DNA in
cancer cells and induce DNA damage either directly
through DNA adduct formation (for example cisplatin) or
indirectly via inhibition of DNA synthesis (for example
gemcitabine and 5-fluoruracil) or DNA unwinding (for
example etoposide). All of these processes result in
DNA strand breaks, activation of the DDR and cell cycle
checkpoints, and ultimately cell cycle arrest. Targeting
the DDR through Chk1 inhibition, therefore, represents
a novel therapeutic strategy to increase DNA-damaging
chemotherapeutic drug induced tumor cell death in p53
pathway defective cancers [9,10] by abrogating the
remaining intact checkpoint. This “synthetic lethality”
approach should increase the therapeutic index of a
given chemotherapeutic drug as normal cells remain
protected by their functional p53 pathway. This ap-
proach has started to be tested clinically with multiple
small molecule inhibitors of Chk1 in clinical evaluation
in Phase I (GDC-0425 and GDC-0575) or Phase II
(LY2603618 [11] and MK-8776 (SCH 900776) [12])
trials in combination with gemcitabine, pemetrexed and
cisplatin [13].
The advent of molecularly targeted cancer therapeu-
tics has resulted in increased emphasis on identifying
pharmacological biomarkers of drug/target interaction
to help accelerate the progress of novel agents through
clinical trials [14-16]. To date, biomarker and clinical
studies of Chk1 inhibitors have predominantly focused
on the combination with gemcitabine. However, Chk1
inhibitors have the potential to be combined with
a wide range of cytotoxic chemotherapeutics. In this
study, we evaluated the potential for a novel, highly
selective Chk1/2 inhibitor, V158411, to potentiate the
cytotoxicity of a range of agents in p53 mutant colon
cancer cells and the corresponding changes in a panel
of potential pharmacodynamic biomarkers for predic-
tors of V158411 combinatorial activity.Methods
Cell lines and cell culture
All cell lines were purchased from the American Type
Culture Collection (ATCC), established as a low pas-
sage cell bank and then routinely passaged in our
laboratory for less than 3 months after resuscitation.
HT29, Colo205 and HCT116 cells were routinely cul-
tured in DMEM containing 10% FCS and 1% penicillin/streptomycin at 37°C in a normal humidified atmos-
phere supplemented with 5% CO2.
Compounds
Solid stocks were purchased from the indicated suppliers
and prepared as concentrated stock solutions in the
appropriate solvent: gemcitabine (Apin Chemicals Inc),
20 mM in H2O; camptothecin (LC Laboratories), 5 mM in
DMSO; cisplatin (David Bull Laboratories), 3.33 mM in
1% NaCl in H2O; oxaliplatin (Tocris), 5 mM in H2O; eto-
poside (Selleckchem), 20 mM in DMSO; doxorubicin
(Selleckchem), 5 mM in DMSO; 5-fluorouracil (Sigma),
50 mM in DMSO; LY2603618 (Selleckchem), 20 mM in
DMSO and MK-8776 (ChemieTek), 20 mM in DMSO.
Potentiation assays
5000 cells per well were seeded in 96-well plates and
incubated overnight. Cells were treated with a 10-point
titration of cytotoxic chemotherapeutic agent in the
presence of a fixed concentration of Chk1 inhibitor for
72 or 168 hours. The effect on cell proliferation was
determined using CellTiter 96 AQueous One Solution
Cell Proliferation Assay (MTS, Promega) and read on a
Victor plate reader (Perkin Elmer).
Anchorage independent growth assays
1500 cells/well in 0.4% low melting point agarose (Sea-
Plaque, Lonza) in complete media were plated on to
96-well plates coated with 0.8% low melting point agarose
in complete media. Wells were subsequently overlaid with
complete media containing cytotoxic chemotherapeutic
agents and Chk1 inhibitor. Following incubation for
168 hours, cell viability was determined using CellTiter
Blue (Promega) and fluorescence determined using a
Victor plate reader (Perkin Elmer).
Spheroid growth assays
Multi-cellular tumor spheroid assays were preformed
essentially as described previously [17]. 1000 HT29 cells/
well were seeded in 96-well round bottomed ultra-low
attachment microplates (Corning Costar), centrifuged
at 1000 × g for 3 minutes and spheroids formed for
72 hours. Spheroid cell viability after incubation with
chemotherapeutic drug plus V158411 for 168 hours
was determined using CellTiter-Glo Luminescent Cell
Viability Assay (Promega).
Immunoblotting
Antibodies against Chk1, pChk1 (S317), pChk1 (S345),
pChk2 (T68), pChk2 (S516), γH2AX, pCdc2 (Y15),
pCdc25c (S216), Cdc25a, phH3 (S10), PARP, cleaved
PARP, 53BP1, cyclin A, cyclin B1, cyclin D, cyclinE,
pCDK2 (T160) and RPA70 were purchased from Cell
Signaling Technologies and pChk1 (S296) from Abcam.
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buffer containing protease and phosphatase inhibitor
cocktails (Roche). Protein concentration was determined
using a BCA kit (Pierce). Equal amounts of lysate were
separated by SDS-PAGE and western blot analysis con-
ducted using the antibodies indicated above
Statistical analysis
Results were analyzed using a Student’s t-Test tool within
the data analysis package provided by Microsoft Excel.
Ethical approval
None of the research in this manuscript involved human
subjects, human material, or human data, or used regu-



































































































































Figure 1 Determination of in vitro potentiation of cytotoxic chemothe
in HT29 and Colo205 cancer cells grown anchorage dependently, anchorag
chemotherapeutic agents with 400 nM V158411. Pf values were calculated
determinations where Pf equals average GI50/average cGI50. *, P < 0.05; **,
response curves for gemcitabine, camptothecin and cisplatin in combinatio
the GI50 (square and dotted line) and cGI50 (circle and line). C. HT29 dose r
DMSO or 400 nM V158411. HT29 cells were grown either anchorage depen
D. Comparison of the single agent GI50 and consequent potentiation facto
(7 day) incubation with gemcitabine, camptothecin or cisplatin with 0 or 4
are the average of at least 3 determinations ± SD.Results
V158411 potentiates the cytotoxicity of
chemotherapeutic agents in p53 mutant colorectal cancer
cell lines
V158411 is a potent, selective inhibitor of recombinant
Chk1 and Chk2 kinases in vitro with IC50s of 3.5 and
2.5 nM [18] respectively but demonstrates a 19-fold
cellular selectivity for Chk1 over Chk2. V158411 poten-
tiated the cytotoxicity of a range of chemotherapeutic
agents in the p53 mutant colon carcinoma cell lines
HT29 and Colo205 growing anchorage dependently,
anchorage independently or as multi-cellular tumor
spheroids (Figure 1A and 1B). The p53 mutant HT29
colon carcinoma cell line has been extensively used to




































































rapeutic agents by V158411. A. Comparison of potentiation factors
e independently or as multicellular tumor spheroids for cytotoxic
from the average GI50 and combination GI50 (cGI50) of at least three
P < 0.01; ND, not determinable; #, Pf > 15. B. 72 hour HT29 dose
n with DMSO or 400 nM V158411 demonstrating the calculation of
esponse curves for gemcitabine following 168 hour treatment with
dently (left graph) or as multi-cellular tumor spheroids (right graph).
r (Pf, triangle and line) following either 72 hour (3 day) or 168 hour
00 nM V158411 in HT29 cells growing anchorage dependently. Values




















Figure 2 Checkpoint activation and DNA damage protein
biomarker responses in HT29 cells following treatment with
cytotoxic chemotherapeutic agents. HT29 cells were treated with
approximately 5-times the single agent GI50 of gemcitabine (Gem,
0.2 μM), camptothecin (CPT, 1 μM), cisplatin (CP, 125 μM), oxaliplatin
(OxPt, 250 μM), doxorubicin (Dox, 3 μM) or etoposide (Etop, 50 μM)
for 24 hours. Changes in protein expression levels were determined
by immunoblotting.
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main test system for this study. Greater potentiation
was observed in both cell lines growing anchorage
dependently compared to anchorage independently.
The combination treatment of V158411 with gemcita-
bine not only reduced the concentration of gemcitabine
required to inhibit the growth of HT29 or Colo205 cells
but also markedly reduced the viability of cells treated
with gemcitabine (Figure 1B). This effect was only ob-
served for the shorter 72 hour incubation. Gemcitabine,
when incubated for a longer time of 168 hours, induced
greater degrees of cell death that was not further po-
tentiated by the addition of V158411 (Figure 1C). The
magnitude of potentiation of chemotherapeutic agent
cytotoxicity by V158411 was dependent on exposure
time for some agents. For example, in HT29 cells growing
anchorage dependently, increased exposure time to
gemcitabine or camptothecin resulted in increased
cytotoxicity of the chemotherapeutic agents as single
agents and subsequent reduced potentiation by V158411
(Figure 1D). In contrast, the potentiation of cisplatin
cytotoxicity by V158411 remained unchanged following
longer incubation.
DNA damage checkpoint activation is cytotoxic
chemotherapeutic agent dependent
The ability of an equitoxic concentration of gemcitabine,
camptothecin, cisplatin, oxaliplatin, doxorubicin or eto-
poside to induce protein biomarker changes associated
with activation of the DNA damage checkpoint was eval-
uated in HT29 cells. Protein biomarker changes induced
in HT29 cells were dependent on the chemotherapeutic
agent. Gemcitabine, camptothecin and etoposide treat-
ment increased Chk1 phosphorylation at S296, S317 and
S345, phosphorylation of Cdc2 at Y15, and CDK2 at
T160 and increased total cyclin A and B1 protein levels
(Figure 2). In comparison, cisplatin, oxaliplatin and
doxorubicin treatment also increased Chk1 S317 phos-
phorylation but not S296 or S345 phosphorylation.
Cyclin D1 levels were also reduced with these three
agents whilst cyclin A and B1 levels remained unchanged.
These differences in protein biomarker changes may be
a reflection of the differential cell cycle perturbations
induced by the various chemotherapeutic drugs.
V158411 inhibits DNA damage induced Chk1
auto-phosphorylation and increases γH2AX in colon
carcinoma cells
To determine the most appropriate biomarkers of V158411
activity, p53 mutant HT29 and Colo205 colon carcinoma
cells were treated with a fixed dose of either gemcita-
bine or camptothecin with an increasing concentration
of V158411 for 24 hours (Figure 3A). V158411 induced
a dose dependent decrease in Chk1 auto-phosphorylation(at S296) and an increase in γH2AX in HT29 and Colo205
cells in combination with gemcitabine and camptothecin.
In HT29 cells, the induction of γH2AX by V158411 was
more pronounced in combination with camptothecin than
with gemcitabine whilst in Colo205 cells, treatment with
V158411 induced γH2AX by roughly equal amounts in
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Exposure of HT29 or Colo205 cells to increasing con-
centrations of gemcitabine, camptothecin, cisplatin or
etoposide in the presence of a fixed concentration of
V158411 for 24 hours, resulted in reduced pChk1 (S296)
with all four cytotoxic agents (Figure 3B). γH2AX induc-
tion was less apparent and appeared dependent on
cytotoxic agent and concentration. Chk1 inhibition in
combination with chemotherapy induced DNA damage
was predicted to have dramatic effects on replication
fork stability and cell cycle arrest. However, at the time
point studied, no difference in pChk1 (S317) or pChk1
(S345) levels could be perceived between cells treated
with DNA damaging agent alone or in combination
with V158411. To understand in more detail the bio-
marker responses therefore following cytotoxic chemo-
therapy in combination with V158411, we evaluated
the effect of concentration, time and schedule on
camptothecin induced biomarker responses. Inhibition
of Chk1 S296, S317 and S345, and Cdc2 Y15 phosphor-
ylation as well as γH2AX induction by V158411 oc-
curred at a wide range of camptothecin concentrations
from 25 to 400 nM (Figure 4A). Treatment with camp-
tothecin followed by V158411 induced an abrogation
of DNA damage induced arrest and an increase of cells
into mitosis (determined by a decrease in pCdc2 (Y15)DMSO Camptothecin Gemcitabine
0 0
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Figure 3 V158411 inhibits DNA damage induced Chk1 auto-phospho
or Colo205 (right) p53 defective colon carcinoma cells were treated with A. 20
of V158411 for 24 hours or B. treated with the indicated concentrations of ge
nM V158411 for 24 hours. Protein expression was characterized by immunobland an increase in phH3 (S10)) compared to treatment
with camptothecin alone.
Duration of exposure to V158411 and camptothecin,
but not schedule of administration, had a significant
effect on observed biomarker changes. Inhibition of
Chk1 S296 phosphorylation occurred within 1 hour of
V158411 administration and was maintained for the
whole 24 hours. In the presence of camptothecin,
V158411 induced rapid phosphorylation (within 1 hour)
of Chk1 at S317 and S345 that reached a maximum
by 6 hours and then decreased again by 24 hours. By
comparison, in the absence of V158411, the induction of
phosphorylation of Chk1 at S317 and S345 by camptothe-
cin was significantly delayed. The kinetics of γH2AX
and phH3 (S10) induction lagged behind Chk1 S317/
S345 phosphorylation being detectable by 6 hours and
reaching maximal induction by 24 hours (Figure 4B).
Administering V158411 either immediately or up to
24 hours after camptothecin did not result in a differ-
ent pattern of biomarker changes (Figure 4C). In all
combination treatment regimens, total Chk1 as well as
phospho-Chk1 S296, S317 and S345 were decreased and
γH2AX increased compared to camptothecin treatment
alone.
To assess the specificity of pChk1 and γH2AX as
biomarkers of cytotoxic chemotherapy plus V158411DMSO Camptothecin Gemcitabine
0 0
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rylation and increases γH2AX in colon carcinoma cells. HT29 (left)
0 nM camptothecin or 100 nM gemcitabine plus varying concentrations
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Figure 4 Pharmacodynamic changes to DNA damage checkpoint and cell cycle proteins in HT29 colon cancer cells by V158411 in
combination with camptothecin. A. HT29 cells were treated with 0 to 400 nM camptothecin (CPT) in the presence of DMSO or 400 nM
V158411 for 24 hours. B. HT29 cells were treated with 100 nM camptothecin plus DMSO or 400 nM V158411 for 1 to 24 hours. UT, untreated control.
C. HT29 cells were treated with 200 nM camptothecin for 0 to 24 hours followed by 400 nM V158411 (+) or DMSO (−) for a further 24 hours. Protein
expression was characterized by immunoblotting.
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the combination GI80 of gemcitabine, camptothecin,
cisplatin, oxaliplatin, doxorubicin or etoposide for
18 hours followed by 0 or 400 nM V158411 for a fur-
ther 24 hours. In combination with all cytotoxics,
V158411 decreased total Chk1 protein levels as well as
pChk1 S296, S317 and S345. γH2AX was induced by
V158411 in combination with all agents except etopo-
side which caused a significant increase in γH2AX as a
single agent (Figure 5). V158411 reduced Cdc2 Y15
and CDK2 T160 phosphorylation following gemcita-
bine, camptothecin, doxorubicin and etoposide treat-
ment but not with either of the platinating agents.
Changes to histone H3 phosphorylation were chemo-
therapeutic agent dependent as were the changes to
Chk2 phosphorylation. Increased apoptosis, as measured
by cleavage of caspase-2 and −3, has been suggested
to be a potential biomarker of Chk1 inhibitor induced
chemosensitization. Increases in PARP, caspase-2 and
caspase-3 cleavage was observed following treatment
of HT29 cells with gemcitabine, camptothecin, cisplatin,oxaliplatin and doxorubicin but not etoposide in com-
bination with V158411 compared to cytotoxic treatment
alone.
The specificity of γH2AX and Chk1 phosphorylation
as general biomarkers of Chk1 inhibitors was evaluated
using three additional, structurally diverse Chk1 inhibi-
tors: LY2603618 [11], MK-8776 (SCH 900776) [12]
and GNE-900 [24] (Figure 6A). LY2603618, MK-8776
and GNE-900 potentiated the cytotoxicity of gemcita-
bine and camptothecin to HT29 colon carcinoma cells
comparably to V158411 in terms of concentration and
level of potentiation (Figure 6B). Biomarker responses
were subsequently evaluated in HT29 cells treated
with gemcitabine or camptothecin in combination with
V158411, LY2603618, MK-8776 or GNE-900. In com-
bination with gemcitabine or camptothecin, 100 or
300 nM V158411, LY2603618, MK-8776 and GNE-900
induced a dose dependent decrease in Chk1 phosphor-
ylation at S296 and S317 and a concomitant increase in
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Figure 5 Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the
Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 μM), camptothecin (0.44 μM), cisplatin (68 μM),
oxaliplatin (131 μM), doxorubicin (1.2 μM) or etoposide (59 μM) for 18 hours followed by DMSO (−) or 400 nM V158411 (+) for a further 24 hours.
Protein expression was characterized by immunoblotting.
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cytotoxic chemotherapy in colon carcinoma cells is p53
status dependent
Potentiation of gemcitabine, camptothecin, cisplatin
and oxaliplatin cytotoxicity by V158411 was dependent
on p53 status. In the p53 wild-type colon cancer cell
line HCT116, V158411 did not potentiate any of
the four cytotoxic chemotherapeutic agents tested
(Figure 7A). In comparison, V158411 potentiated all
four agents by greater than 5-fold in the HT29 colon
carcinoma cell line which harbors a R273H mutation
in p53. The pharmacodynamic biomarker response of
HCT116 cells to either gemcitabine or camptothecin
in combination with V158411 was evaluated. In combin-
ation with gemcitabine, V158411 treatment reduced Chk1
auto-phosphorylation in addition to total Chk1 protein
levels and decreased phosphorylation of Cdc2 at Y15.
These changes to Chk1 activity however, did not result
in an increase in γH2AX (Figure 7B). Likewise, incombination with camptothecin, V158411 treatment
again resulted in a decrease in pChk1 (S296), total
Chk1 and pCdc2 (Y15) and no change in γH2AX pro-
tein levels compared to DMSO or V158411 treatment
alone (Figure 7C). The response of a wide range of
biomarkers in HT29 and HCT116 cells to camptothe-
cin or oxaliplatin in combination with V158411 was
evaluated. As was observed previously, in the p53
mutant HT29 cells, V158411 in combination with
either camptothecin or oxaliplatin reduced Chk1 phos-
phorylation at S296, S317 and S345 as well as total
Chk1 protein levels resulting in increased γH2AX. In
HCT116 cells, similar changes to Chk1 protein levels
and phosphorylation were observed but in this cell line
did not correlate with an increase in γH2AX (Figure 7D).
Whilst the HT29 and HCT116 cell lines are both de-
rived from the same tissue type, they are non-isogenic
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Figure 6 Potentiation of gemcitabine and camptothecin cytotoxicity and protein biomarker changes induced in HT29 cells by
structurally diverse Chk1 inhibitors. A. Chemical structures of Chk1 inhibitors. B. Potentiation of gemcitabine (Gem) or camptothecin (CPT)
cytotoxicity in HT29 cells following 72 hour exposure in combination with 300 nM V158411, LY2603618, MK-8776 or GNE-900. The potentiation
factor (Pf) was calculated as GI50 cytotoxic agent alone/GI50 cytotoxic agent plus Chk1 inhibitor. Values represent the average of 3 determinations ± SD.
C. Biomarker changes induced in response to gemcitabine plus Chk1 inhibitor treatment in HT29 colon carcinoma cells. HT29 colon cancer
cells were exposed to 50 nM gemcitabine (+) for 16 hours followed by increasing concentrations of Chk1 inhibitor for a further 24 hours.
Protein expression was characterized by immunoblotting. D. Biomarker changes induced in response to camptothecin plus Chk1 inhibitor
treatment in HT29 colon carcinoma cells. HT29 colon cancer cells were exposed to 100 nM camptothecin for 16 hours followed by 100 or 300
nM Chk1 inhibitor for a further 24 hours.
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cytotoxicity by V158411 occurs independently of fetal
calf serum or oxygen concentration and under anchorage
independent growth conditions
The ability of V158411 to potentiate gemcitabine or
camptothecin cytotoxicity under conditions that more
closely reflect in vivo tumor growth conditions, namely
anchorage-independent growth, hypoxia or low nutrient
growth conditions, were evaluated. Potentiation of gem-
citabine or camptothecin cytotoxicity by V158411 was
unaffected by growth of HT29 cells under low (0.5%)FCS or hypoxic (0.1% O2) conditions (Figure 8A). Under
hypoxic growth conditions, the potentiation of gemcita-
bine or camptothecin cytotoxicity increased from 8.6
to 10.0-fold for gemcitabine and from 5.5 to 7.8-fold
for camptothecin compared to normoxic growth. Like-
wise, in low FCS growth conditions, the potentiation of
gemcitabine or camptothecin cytotoxicity by V158411
remained approximately equal to that induced in high
FCS growth conditions (8.5 versus 8.6-fold for gemci-
tabine and 4.9 versus 5.5-fold for camptothecin). In com-
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Figure 7 Comparison of protein biomarker changes in p53 proficient and deficient colon cancer cell lines. A. Potentiation of the
cytotoxicity of gemcitabine (Gem), camptothecin (CPT), cisplatin (CP) or oxaliplatin (OxPt) by 400 nM V158411 was determined in p53 mutant
HT29 or p53 wild-type HCT116 colon cancer cells after 72 hours. GI50 and cGI50 were calculated from the dose response curves using XLFit. The
potentiation factor (Pf) was calculated as GI50/cGI50. Protein biomarker changes were assessed in HCT116 cells treated with B. 50 to 800 nM
gemcitabine or 120 nM camptothecin in combination with 0 (−) or 400 nM (+) V158411 for 24 hours or C. camptothecin plus 0 (−) or 400 nM (+)
V158411 for various time combinations and dosing regimens. D. HT29 or HCT116 cells were treated with the single agent IC80 of camptothecin (HT29,
0.43 μM; HCT116, 0.44 μM) or oxaliplatin (HT29, 131 μM; HCT116, 74 μM) for 18 hours followed by DMSO (−) or 400 nM (+) V158411 for a further
24 hours. Protein expression was characterized by immunoblotting.
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in HT29 cells grown under normoxic, hypoxic or low
FCS conditions (Figure 8A).
V158411 potentiated the cytotoxicity of gemcitabine in
HT29 cells growing anchorage dependently or independ-
ently (Figure 8B). The potentiation observed in HT29
cells in anchorage dependent culture (Pf 8.6) was greater
than that observed in anchorage independent growth in
low melting point agarose (Pf 3.6) or as multi-cellular
tumor spheroids (Pf 2.1). In HT29 multi-cellular tumor
spheroids, the combination treatment of gemcitabine plus
V158411 reduced Chk1 auto-phosphorylation (S296) and
increased Chk1 phosphorylation at S345 and γH2AX
levels albeit at higher concentrations of V158411 than that
required under normal anchorage dependent growth con-
ditions (Figure 8B).
Discussion
Seven structurally distinct inhibitors of the serine/threo-
nine checkpoint kinase Chk1 have been evaluated or arecurrently being actively tested in combination clinical
trials with a range of cytotoxic chemotherapy drugs such
as irinotecan, cisplatin, gemcitabine, pemetrexed and
cytarabine. These include XL844, AZD7762 and PF477736
which completed Phase I trials and LY2603618 which
completed Phase II, but further development of these
agents has subsequently been discontinued. GDC-0425
and GDC-0575 continue to be actively developed in a
Phase I setting and MK-8776 (SCH 900776) in Phase II. It
is interesting to note that all Chk1 inhibitors so far tested
in combination clinical trials (seven to date) have under-
gone clinical testing in combination with gemcitabine
(ClinicalTrials.gov) whilst pemetrexed, cisplatin, irinotecan
or cytarabine have been tested with only one Chk1 inhibi-
tor each [25-28].
In this study, we evaluated the ability of the novel
Chk1 inhibitor V158411 to potentiate the in vitro cyto-
toxicity of seven clinically used cytotoxic chemotherapy
drugs with different mechanisms-of-action in two p53




















































































































































Figure 8 Potentiation of gemcitabine and camptothecin cytotoxicity by V158411 occurs independently of fetal calf serum or oxygen
concentration and under anchorage independent growth conditions. A. Potentiation of the cytotoxicity of gemcitabine or camptothecin by
400 nM V158411 was determined in HT29 cells growing in 10% FCS, 21% O2 (normoxia); 10% FCS, 0.5% O2 (hypoxia) or 0.5% FCS, 21% O2 for 72 hours.
GI50 and cGI50 were calculated from the dose response curves using XLFit. The potentiation factor (Pf) was calculated as the average GI50/average
cGI50 from 3 determinations. Protein biomarker changes were subsequently assessed in HT29 cells growing under the same conditions following
treatment with 100 nM gemcitabine plus 0 to 1000 nM V158411 for 24 hours. B. HT29 cells growing either attached to plastic cell culture plates
(anchorage dependently), anchorage independently in LMP agarose or as multicellular tumor spheroids were exposed to increasing concentrations
of gemcitabine in the presence or absence of 400 nM V158411 for 72 (anchorage dependent) or 168 (anchorage independent/spheroid) hours.
**, P < 0.01. Protein biomarker changes were assessed in HT29 cells growing anchorage dependently or as multi-cellular tumor spheroids following
treatment with 100 nM gemcitabine plus 0 to 1000 nM V158411 for 24 hours. Protein expression was characterized by immunoblotting.
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independently or as multi-cellular tumor spheroids. Ana-
lysis of in vitro protein biomarker responses was subse-
quently undertaken in an attempt to identify biomarkers
potentially predictive of combinatorial activity.
V158411 induced moderate to good potentiation of all
seven cytotoxic agents tested in the two p53 mutant cell
lines but not the p53 wild-type cell line. The only excep-
tion was with 5-fluorouracil in the HT29 cell line. The
lack of potentiation of 5-fluorouracil activity in this cell
line was most likely due to the high intrinsic resistance
of HT29 cells to 5-fluorouracil (GI50 > 100 μM for single
agent). Greater potentiation was observed for cells
growing anchorage dependently than cells growing
either anchorage independently or as multi-cellular
tumor spheroids and may be a reflection of the in-
creased rate of proliferation and/or the fraction of cells
undergoing active DNA replication in the anchorage
dependent culture conditions. In short term combin-
ation studies (3 day co-incubation), gemcitabine was
the only agent for which V158411 not only potentiated
the anti-proliferative activity of the cytotoxic agent but
also increased the fraction of cells killed at the higher
concentrations of drug. This increased cell killing wasonly observed for the short 3 day incubation and was
subsequently lost at longer incubations possibly due to
the increased cytotoxicity of gemcitabine as a single
agent.
Previously published studies have observed the great-
est potentiation of cytotoxicity by Chk1 inhibitors with
the anti-metabolite class of drugs, including gemcitabine
[23]. Chk1 activity has been demonstrated to be critical
for not only the DNA damage response checkpoint but
also for replication fork stabilization, replication origin
firing and homologous recombination. These later roles
have been suggested to be critical for the increased
effectiveness of Chk1 inhibitors in combination with
gemcitabine [29] compared to other cytotoxic chemo-
therapy drugs such as Topoisomerase inhibitors. Gemci-
tabine inhibits DNA synthesis, DNA replication and cell
proliferation through two distinct but linked mecha-
nisms. Gemcitabine diphosphate binds to and irreversibly
inhibits ribonucleotide reductase thereby depleting the
pool of deoxyribonucleotides available for de novo DNA
synthesis. The triphosphate analogue of gemcitabine can
also be incorporated into DNA (in substitution for cyti-
dine) where it acts as a chain terminator thereby inhibiting
further DNA synthesis. Inhibition of ribonucleotide
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induces replication fork stalling. Chk1 activity is required
to maintain replication fork stability and inhibition of
Chk1 leads to replication fork collapse and the generation
of “new” DNA strand breaks. In p53 mutant cancer cells,
the checkpoint is functionally inactivated by Chk1 inhib-
ition, therefore these cells progress through S-phase and
enter into a premature, lethal mitosis [30]. Replication fork
collapse and checkpoint abrogation by Chk1 inhibitors
induces potentially lethal DNA damage killing gemcita-
bine treated p53-mutant cancer cells by a “double hit”
mechanism. It should however be noted that the potenti-
ation of gemcitabine observed in pre-clinical xenograft
studies is not nearly as dramatic as that observed in the
in vitro potentiation studies. The pre-clinical combination
studies of gemcitabine in combination with Chk1 inhibi-
tors are generally conducted at gemcitabine concentra-
tions below the gemcitabine maximum tolerated dose
and using a schedule (once every 3 days) that is not
reflective of the clinical schedule (once weekly). Our
studies suggest that other cytotoxic drugs such as
cisplatin or oxaliplatin, in addition to gemcitabine, are
worthy of further evaluation.
One of the challenges, and goals, of molecularly
targeted cancer therapeutic development is the identi-
fication of biomarkers (whether they be genetic,
protein or macromolecule based) that allow the trans-
lation of the understanding and knowledge gained at
the molecular and cellular level into a therapy effective
for patients [14-16]. These biomarkers can be identi-
fied and developed for one of three specific aims: 1, to
stratify a patient population into potential responders
and non-responders, 2, to ensure adequate target en-
gagement or inhibition at a given dose or 3, to assess
for pathway modulation and a potentially positive or
beneficial therapeutic outcome. The overall aim of bio-
marker development and utilization is to accelerate the
clinical development and adoption of new anti-cancer
therapies.
Previous studies have demonstrated that a deficiency
in p53 improves chemopotentiation by Chk1 inhibitors
[23]. However, mutation of p53 has been found to be
important for overall response but is not sufficient to
predict a synergistic outcome between a Chk1 inhibitor
and cytotoxic chemotherapy. BRCA, XRCC3, DNA-PK
[31] and CYCLIN B1 [32] levels have all been postu-
lated to be important in modulating the effectiveness
of a Chk1 inhibitor in combination with a DNA dam-
aging agent. In our study, we attempted to correlate
potentiation of DNA damaging agent cytotoxicity by
the Chk1 inhibitor V158411 with protein biomarker
changes induced by the combination to identify bio-
marker changes predictive of a robust, combinatorial
effect.Phosphorylation of Chk1 on serine 345, an activation
phosphorylation site on Chk1 phosphorylated in response
to DNA damage by ATR, correlated closely with response
to the combination of gemcitabine plus AZD7762 in
pancreatic tumor xenografts [33]. In a separate study,
cleaved (activated) caspase-2 levels increased in re-
sponse to DNA damage when Chk1 was inhibited due
to checkpoint inactivation and forced mitotic entry [34].
However, other studies have demonstrated that death
induced by the combination of a DNA damaging drug
and Chk1 inhibitor was not always dependent on caspase-
2 or the PIDDosome [35]. In our study, moderate to high
potentiation was observed with all of the DNA damaging
agents tested in the p53 mutant but not the p53 wild-type
colon cancer cell lines. No unifying biomarker was iden-
tified that would appear predictive of effective combina-
torial activity. Instead, as might be predicted, biomarker
responses appeared DNA damaging agent specific. Add-
itionally, there was dependence on post-treatment time
to observe optimal biomarker changes but these re-
sponses were less dependent on the schedule of addition
of DNA damaging agent and V158411.
In all combinations, V158411 efficiently reduced the
levels of auto-phosphorylated (pSer296) Chk1 sug-
gesting that Chk1 was effectively inhibited by the
concentration of V158411 utilized. pChk1 (S296) would
therefore make a powerful biomarker for ensuring
effective target engagement and Chk1 inhibition in
clinical samples. In combination with all DNA dam-
aging drugs, V158411 induced a time dependent deg-
radation of Chk1. This may, in part, reflect the normal
homeostatic process of cellular checkpoint resetting.
A reduction in total Chk1 S317 and S345 phosphoryl-
ation occurred most consistently with all cytotoxics in
combination with V158411 but did not predict cell
line sensitivity as similar biomarker changes were ob-
served in the non-responsive, p53 wild-type HCT116
cell line. Induction of γH2AX expression was chemo-
therapeutic dependent and correlated closely with po-
tentiation for gemcitabine and camptothecin in p53
mutant but not wild-type colon cancer cells. These
protein biomarker changes appeared to not depend on the
chemical structure of the CHk1 inhibitor as a similar pat-
tern of changes was observed with a range of Chk1 inhibi-
tors with diverse chemotypes. Assays to measure γH2AX
are reasonably well developed and are currently being
tested clinically with different cancer therapeutics and
may therefor prove a relatively straightforward marker
to include in clinical studies [36-38].
Conclusions
Our results suggest that reduction in Chk1 phosphoryl-
ation at serine 296 could be a useful biomarker for
monitoring Chk1 activity, and its subsequent inhibition,
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chemotherapy combinations. γH2AX induction in combi-
nations containing gemcitabine or camptothecin could
potentially serve as a predictive marker of pathway
modulation and therapeutic outcome.
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